A Prescription Drug User Fee Act target date of December 27, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR ...
To learn more about the use of meloxicam for treating OA, RA, and JIA, see the “What is meloxicam used for?” section below. * Meloxicam may also be used to treat certain conditions in dogs and cats.
Zacks.com on MSN
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Viatris VTRS announced that the FDA has accepted the new drug application (NDA) for review for MR-107A-02, a fast-acting meloxicam formulation being developed as a non-opioid treatment for moderate-to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results